Long‐term survival and toxicity in patients with neuroendocrine tumors treated with 177Lu‐octreotate peptide radionuclide therapy

Authors:

Abstract
Background: Peptide receptor radionuclide therapy (PRRT) has shown favorable results in neuroendocrine tumors (NETs). Long‐term safety and efficacy data for 177Lu‐octreotate PRRT, particularly in combination with chemotherapy, is lacking.Methods: The authors conducted a retrospective review of the long‐term toxicity and survival outcomes of 104 patients with advanced NETs treated on 4 phase 2 clinical trials with Lutetium‐177‐octreotate (177Lu‐octreotate) PRRT, mostly in combination with chemotherapy. Median follow‐up was 68 months, which represents the longest follow‐up study of 177Lu‐octreotate PRRT for NETs to date.Results: Median progression‐free survival (PFS) was 37 months, and median overall survival (OS) was 71 months. Five‐ and 10‐year OS were 62% and 29%, and 5‐ and 10‐year PFS were 36% and 21%, respectively, demonstrating 177Lu‐octreotate can provide durable responses. PRRT was well tolerated with 1.9% of patients developing chronic renal impairment and 1% of patients developing long‐term thrombocytopenia. Interestingly, there was a relatively high rate of myelodysplasia (MDS)/leukemia (6.7%), possibly attributable to the longer follow‐up (with all except 1 case occurring more than 4 years after PRRT treatment) or to the addition of concurrent chemotherapy.Conclusions: Lutetium‐177‐Octreotate PRRT remains an efficacious and well tolerated treatment in long‐term follow‐up. For clinicians deciding on the timing of PRRT for individual patients, the 6.7% long‐term risk of MDS/leukemia needs to be balanced against the 21% PFS at 10 years.

This publication has 26 references indexed in Scilit: